Mounjaro®
Starting from £179.99/mo
Start journey Learn moreMost people do not see significant weight loss in the first week on Wegovy. The starting dose of 0.25mg is a tolerability dose — its job is to help your body adjust, not to drive fat loss. Meaningful weight reduction typically builds over weeks and months, as shown in the STEP 1 trial published in the New England Journal of Medicine, which reported an average 15% body-weight reduction over 68 weeks in adults without diabetes. That context matters, because a lot of people starting treatment expect the scales to move in days — and feel disappointed when they don't. Wegovy is a prescription-only medicine; a clinician assesses whether it's appropriate for you before treatment begins.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The STEP 1 trial is the core evidence base for semaglutide 2.4mg (Wegovy). In that study, 1,961 adults with obesity or overweight took part over 68 weeks alongside lifestyle support. The headline figure (roughly 15% average body-weight reduction) is drawn from the full treatment period, not the opening weeks. Participants started at 0.25mg and were titrated upward over approximately 16 weeks before reaching the 2.4mg maintenance dose. The trial data show that weight loss accelerated meaningfully once higher doses were reached. Week one results, on a starter dose, are a small fraction of what the full programme delivers.
The NHS semaglutide medicines page reflects this: it describes Wegovy as a treatment where effects build progressively, and it frames the escalation schedule as central to how the medicine works, not an inconvenience to be rushed through.
A common misconception is that a slow first week means the medicine isn't working. It almost always does. The 0.25mg dose is there to reduce early nausea and give your digestive system time to adapt, losing weight quickly on it would actually be unusual. If you want to know what weight loss in the first week of Wegovy actually looks like, the realistic picture is more modest than most people expect, and that is entirely normal. Letting that expectation go early tends to make the whole experience easier.
Even if the scales barely move, most people do feel something shift in the first week. Appetite often feels different, meals feel more satisfying with less food, and the urge to snack between meals can quiet down noticeably. Some people experience a small drop in fluid retention, which can register as a pound or two on the scales and can be mistaken for fat loss (or cause disappointment when it doesn't continue at that pace).
Common side effects are also most likely to appear early: nausea, a feeling of fullness that lingers, some people notice constipation or loose stools in the first few days. These usually settle. If you want a fuller picture of how the first week typically feels beyond just weight, the Wegovy first week guide covers the experience in detail.
One practical thing worth noting: semaglutide slows gastric emptying, which is part of how it reduces appetite. That same mechanism is what causes the GI symptoms some people experience early on. It is the medicine doing exactly what it is supposed to do.
For most people, noticeable weight loss starts becoming apparent somewhere between weeks four and twelve, as the dose increases. The titration schedule moves from 0.25mg to 0.5mg, then 1.0mg, 1.7mg, and eventually 2.4mg, each step roughly four weeks apart, subject to tolerability. Weight loss tends to track with dose escalation rather than with calendar time from the first injection.
If you are thinking about how results evolve over a longer window, the first month on Wegovy covers what most people realistically experience across the full initial phase. And for a broader sense of the timeline, how long Wegovy takes to work walks through what the evidence says at each stage.
What the STEP 1 data make clear is that the treatment rewards patience. Average weight loss continued accumulating well past the midpoint of the trial. People who stuck with the programme at higher doses saw far greater results than those who stopped early or never reached maintenance dosing.
Wegovy is a prescription-only medicine, and the prescriber's role doesn't end at week one. A clinician reviews your consultation before treatment starts, and every repeat order goes through a fresh clinical check, dose increases require evidence, not just a request. Our prescribers review consultations the same day; if you order before 12pm on a working day and are clinically approved, treatment is dispatched that afternoon and delivered free the next working day by DPD, in plain packaging.
If you're weighing up the cost side of private treatment, the Wegovy pricing page sets out what a legitimate private prescription includes. And if you'd like to understand the full treatment picture before deciding, the Wegovy overview is a good place to start. When you're ready, you can start a free consultation and a prescriber will assess whether Wegovy is right for you.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.